Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4700417 | 1.00 | PREP (0.40) | PREPCASP1F2SMN1; SMN2CYP2C19 | |
| SCHEMBL7845558 | 0.89 | ALDH1A1 (0.44) | PREPSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL13244922 | 0.89 | ALDH1A1 (0.44) | PREPSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL4701620 | 0.89 | ALDH1A1 (0.44) | PREPSMN1; SMN2CYP2C19NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL4701828 | 0.88 | ALDH1A1 (0.43) | PREPSMN1; SMN2CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4700390 | 0.88 | ALDH1A1 (0.43) | PREPSMN1; SMN2CYP2C19ALDH1A1 | |
| SCHEMBL13244810 | 0.84 | ALDH1A1 (0.42) | PREPSMN1; SMN2CYP2C19NPC1RAB9A | |
| Bromide SCHEMBL3119410 | 0.83 | ALDH1A1 (0.41) | PREPSMN1; SMN2CYP2C19NPC1RAB9A | |
| Bromide SCHEMBL3119408 | 0.83 | ALDH1A1 (0.41) | PREPSMN1; SMN2CYP2C19NPC1RAB9A | |
| Bromide SCHEMBL3119404 | 0.82 | PREP (0.40) | PREPSMN1; SMN2CYP2C19NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | PREP 66/4885CASP1 675/4885F2 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.